ACR 2025 Economics Forum
The Economics Forum at ACR 2025 highlighted recent successes including coverage of CT colonoscopy for Medicare patients and new CPT codes for MRI safety.
Read moreMain Content
NRC Releases New Guidance For Training and Experience Requirements
May 1, 2025
The U.S. Nuclear Regulatory Commission (NRC) released the final version of the Interim Staff Guidance, which reflects stakeholder comments submitted in response to an August 2024 request for comment about the draft interim staff guidance. The document provides guidance for implementing the training and experience (T&E) requirements. The American College of Radiology (ACR®) submitted comments regarding the draft guidance in November.
The guidance identifies the information that licensees or applicants must provide to demonstrate that they have met the T&E requirements to be authorized for the medical use of byproduct material as authorized users (AUs), radiation safety officers (RSOs), associate radiation safety officers (ARSOs), authorized nuclear pharmacists (ANPs), authorized medical physicists (AMPs) and ophthalmic physicists (OPs). It also provides instructions on how to amend an existing medical use license to include additional authorized individuals. Further, the document provides guidance on requirements for completing continuing education (CE) if the individual obtained the required T&E more than 7 years preceding the date of the licensing application. In addition to providing instructions for licensees and applicants, the guidance provides guidelines for NRC staff and Agreement States to evaluate applications or license amendment requests.
The guidance does not replace existing regulations or establish new requirements for meeting the T&E requirements. Instead, the guidance clarifies various past guidance and consolidates them into one document to improve efficiency and accessibility. The NRC notes that licensees, applicants, Agreement States and NRC staff should use the guidance in addition to the Consolidated Guidance about Materials Licenses, which provides program-specific guidance about medical use licenses. The NRC notes that stakeholders should use this guidance until it is superseded by future rulemaking related to T&E for emerging medical technologies.
For more information or if you have questions about the guidance, contact Lindsay Robbins, ACR Regulatory Policy Specialist.
The guidance identifies the information that licensees or applicants must provide to demonstrate that they have met the T&E requirements to be authorized for the medical use of byproduct material as authorized users (AUs), radiation safety officers (RSOs), associate radiation safety officers (ARSOs), authorized nuclear pharmacists (ANPs), authorized medical physicists (AMPs) and ophthalmic physicists (OPs). It also provides instructions on how to amend an existing medical use license to include additional authorized individuals. Further, the document provides guidance on requirements for completing continuing education (CE) if the individual obtained the required T&E more than 7 years preceding the date of the licensing application. In addition to providing instructions for licensees and applicants, the guidance provides guidelines for NRC staff and Agreement States to evaluate applications or license amendment requests.
The guidance does not replace existing regulations or establish new requirements for meeting the T&E requirements. Instead, the guidance clarifies various past guidance and consolidates them into one document to improve efficiency and accessibility. The NRC notes that licensees, applicants, Agreement States and NRC staff should use the guidance in addition to the Consolidated Guidance about Materials Licenses, which provides program-specific guidance about medical use licenses. The NRC notes that stakeholders should use this guidance until it is superseded by future rulemaking related to T&E for emerging medical technologies.
For more information or if you have questions about the guidance, contact Lindsay Robbins, ACR Regulatory Policy Specialist.